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Abstract
Background: Pulmonary vascular abnormalities are a characteristic feature of chronic obstructive pulmonary disease
(COPD). Cigarette smoking is the most important risk factor for COPD. It is believed that its constant exposure triggers
endothelial cell damage and vascular remodelling. Under pathological conditions, progenitor cells (PCs) are mobilized
from the bone marrow and recruited to sites of vascular injury. The aim of the study was to investigate whether in
COPD the number of circulating PCs is related to the presence of bone marrow-derived cells in pulmonary arteries and
the association of these phenomena to both systemic and pulmonary endothelial dysfunction.
Methods: Thirty-nine subjects, 25 with COPD, undergoing pulmonary resection because of a localized carcinoma, were
included. The number of circulating PCs was assessed by flow cytometry using a triple combination of antibodies
against CD45, CD133 and CD34. Infiltrating CD45+ cells were identified by immunohistochemistry in pulmonary
arteries. Endothelial function in systemic and pulmonary arteries was measured by flow-mediated dilation and
adenosine diphosphate-induced vasodilation, respectively.
Results: COPD patients had reduced numbers of circulating PCs (p < 0.05) and increased numbers of CD45+ cells
(< 0.05) in the pulmonary arterial wall than non-COPD subjects, being both findings inversely correlated (r = − 0.35,
p < 0.05). In pulmonary arteries, the number of CD45+ cells correlated with the severity of vascular remodelling (r = 0.4,
p = 0.01) and the endothelium-dependent vasodilation (r = − 0.3, p = 0.05). Systemic endothelial function was unrelated
to the number of circulating PCs and changes in pulmonary vessels.
Conclusion: In COPD, the decrease of circulating PCs is associated with their recruitment in pulmonary arteries, which
in turn is associated with endothelial dysfunction and vessel remodelling, suggesting a mechanistic link between these
phenomena. Our findings are consistent with the notion of an imbalance between endothelial damage and repair
capacity in the pathogenesis of pulmonary vascular abnormalities in COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is a
highly prevalent, non-curable, life-threatening disease,
characterised by irreversible changes in lung structures
[1–3]. Pulmonary vascular abnormalities, as shown by
alterations in vessel structure, abnormal cell growth,
endothelial dysfunction and resistance to apoptosis, are
characteristic features in COPD [4, 5]. An altered
pulmonary vascular function in COPD patients may pre-
dispose to pulmonary hypertension, which is associated
with adverse outcomes [6]. Growing evidence suggests
that endothelial cell damage found in pulmonary vessels
of COPD patients is an initial and important triggering
factor that promotes pulmonary vascular remodelling
[5]. It has been shown that COPD patients present
endothelial dysfunction in both pulmonary and systemic
arteries at early disease stages [7–9]. This endothelial
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damage may result from an imbalance between vascular
injury and the body’s repair capacity [10].
Bone marrow-derived progenitor cells (PCs) are a
population of rare, pre-differentiated adult stem cells
that circulate in the blood with the ability to proliferate
and differentiate into mature endothelial cells [11].
Although, the contribution of PCs in vascular remodel-
ling and repair is unclear, it is believed that under patho-
logical conditions, PCs are mobilized from the bone
marrow and recruited to sites of vascular injury to main-
tain vascular homeostasis [7]. PCs are believed to be
essential in maintenance of the endothelium’s integrity
and restoration of normal function, replacing terminally
differentiated cells lost as a consequence of physiological
cell turnover or tissue damage [12]. Conversely, it has
also been suggested that in COPD, PCs mobilization and
recruitment may contribute to COPD pathogenesis. PCs
intrinsic dysfunctional activity, mainly due to cigarette
smoke (CS) exposure, promotes inflammation, pulmon-
ary vessel remodelling and pulmonary hypertension [13].
Reduced number and function of circulating PCs has
been established as an independent prognostic factor
associated with endothelial dysfunction, high cardiovas-
cular risk and increased mortality [14–16]. In COPD,
few studies to date have investigated the number of
circulating PCs [10, 12, 17]. We and others have previ-
ously shown reduced levels of circulating PCs in COPD
patients, as compared to controls [10, 12, 17]. To date,
two different mechanisms have been suggested to ex-
plain the reduced number of circulating PCs seen in
COPD, an impairment of the bone marrow to generate
enough circulating PC numbers and/or an increased PC
recruitment in pulmonary vessels in response to tissue
injury. Accordingly, in this study we aimed to quantify
in the same individuals both circulating PCs and bone
marrow-derived cells localized in pulmonary arteries, as
well as their association to pulmonary artery remodel-
ling, and systemic and pulmonary artery functionality.
Methods
Subjects
Thirty-nine subjects, aged between 48 and 70 years,
undergoing pulmonary resection because of a localized
lung carcinoma were enrolled in the study. Patients were
divided into two groups: (a) a non-COPD group (n = 14)
with normal pulmonary function, and (b) a COPD
patient group (n = 25), defined by a forced expiratory
volume in the first second (FEV1)-to-forced vital cap-
acity (FVC) ratio lower than 0.7. Patients with COPD
were on regular bronchodilator treatment and some of
them received inhaled corticosteroids. Before surgery, all
patients underwent standard evaluation by means of
medical history, clinical examination and pulmonary
function tests (forced spirometry, lung volumes, carbon
monoxide diffusing capacity (DLco), and arterial blood
gas analysis), as previously described [18]. Plasma levels
of endothelin-1, nitrites/nitrates, angiopoietin-2 and
brain natriuretic peptide (BNP) were also measured. The
study was conducted in accordance with the Declaration
of Helsinki, approved by the institutional Committee on
Human Research and all subjects gave written informed
consent.
Circulating CD45+CD34+CD133+progenitor cells
The number of circulating progenitor cells was evaluated
by flow cytometry using antibodies against CD45 (pan--
leukocyte marker), CD133 (sub-population of haemato-
poietic stem cells) and CD34 (mature and progenitor
endothelial cells) as previously described [10, 17, 19]. In
brief, mononuclear cells (MNCs) were isolated by Ficoll
density gradient separation, washed once with phosphate
buffered saline (PBS) supplemented with 2% foetal calf
serum (FCS) and resuspended at 2 × 106 cells (control
tube) and at 4 × 106 cells (sample tube). Peripheral blood
mononuclear cells were stained and analysed for pheno-
typic expression of surface markers using pre-conjugated
anti-human monoclonal antibodies: anti-CD45-FITC,
anti-CD34-PECy7 and anti-CD133-PE. The fluorescence
minus one technique [10, 17, 20] was employed to
provide negative controls. After 45 min of incubation,
cells were washed, resuspended into 500ul of PBS +
2%FCS and proceeded to flow-cytometric analysis.
Eighty thousand events were gated in the lymphocyte
region as preciously described [10, 17].
Endothelial function in systemic and pulmonary arteries
Systemic endothelial function assessment
Endothelial function was assessed by high resolution
ultrasound as the change in brachial artery diameter in
response to reactive hyperaemia (flow-mediated dilation),
as previously described [21]. Endothelium-independent,
nitroglycerine-mediated dilation was also measured.
Endothelial pulmonary artery function assessment
Endothelial function of pulmonary artery segments was
evaluated in vitro as previously described [4, 22]. Arterial
segments with an external diameter of approximately 2
mm were carefully dissected free of visible fat and con-
nective tissue and cut into 3 mm long rings. All rings
were submaximally pre-contracted with norepinephrine
(NE; 10− 7 to 10− 6 M) to obtain a stable plateau of ten-
sion. Rings were tested using cumulative concentrations
of adenosine diphosphate (ADP) (10− 10 to 10− 4 M), an
endothelium-dependent vasodilator. Relaxation of each
pulmonary artery ring was determined by measuring the
reduction in tone in response to cumulative doses of the
vasodilating agent and expressed as the percent reduc-
tion from the value recorded after pre-contraction with
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NE. Maximal relaxation was the greatest reduction in
tone in response to the vasodilator.
Number of CD45+ cells in pulmonary arteries
Cryostat sections of PBS-4% paraformaldehyde-fixed
artery rings were immunostained using the avidin-biotin
complex/horseradish peroxidase method (Vector La-
boratories). We used a mouse monoclonal antibody
against the pan-leukocyte marker CD45 (diluted 1/750)
(Novocastra Laboratories) and a progenitor cell marker
CD133 (diluted 1/5) (Miltenyi Biotec) for immunolocal-
ization of bone marrow-derived cells. Negative control
experiments were conducted omitting the primary anti-
body. The number of positive cells infiltrating the arter-
ial wall were counted and expressed as cell number per
square millimetre of intimal surface as previously
described [22].
Morphometric studies
Pulmonary muscular arteries were analysed in formalin-
fixed paraffin-embedded lung tissue sections processed
with elastic orcein stain. All arteries with an external
diameter < 1 mm and with complete elastic laminas were
evaluated using a specific software package (Leica-Qwin)
as previously described [23]. Briefly, the external diam-
eter was measured as the widest distance between
external elastic laminas, perpendicular to the greatest
longitudinal axis of each artery. Arterial wall thickness
of each pulmonary artery was calculated as the area of
the arterial wall divided by the internal perimeter and
expressed as percentage of radius. All arteries with an
index of narrowing (smaller diameter divided by larger
diameter) lower than 1/3 were rejected.
Data analysis
Data are expressed as mean ± SD. Comparisons between
groups were performed using Mann-Whitney U-test.
Spearman rank correlation was used to assess correla-
tions between variables. A p value < 0.05 was considered
statistically significant.
Results
General patient’s characteristics
The COPD and non-COPD groups were well matched
with respect to age and body mass index. Both groups
showed a high percentage of male subjects. Five patients
in the non-COPD group had never smoked. Approxi-
mately, half of the patients in each group were current
smokers. All COPD patients were current or ex-smokers
(Table 1). COPD patients had moderate-to-severe air-
flow limitation, moderately reduced DLco and mild
hypoxemia. There were no differences in the Framing-
ham risk score between groups. The number of leuko-
cytes, monocytes, lymphocytes and neutrophils were
similar in both groups. COPD patients presented lower
platelet counts than non-COPD subjects (Table 1).
Levels of endothelin-1, angiopoietin-2, C-reactive pro-
tein, fibrinogen, nitrites/nitrates, VEGF, IL-6, BNP and
VEGR2 did not differ between groups (Table 1).
COPD patients showed lower number of circulating
CD45+CD34+CD133+cells and greater number of CD45+
cells in pulmonary arteries than non-COPD subjects
Circulating progenitor cells, defined as CD45+CD34+
CD133+cells were significantly reduced in COPD pa-
tients compared with the non-COPD group (Fig. 1a).
Conversely, COPD patients had a higher number of
CD45+ cells in pulmonary arteries than non-COPD
subjects (Fig. 1b). Representative histological pictures
showed CD45+and CD133+ cells localized within the
intima of pulmonary arteries (Additional file 1: Figure
S1a-b). There was a significant inverse correlation be-
tween the number of circulating CD45+CD34+CD133+
cells and the number of CD45+ infiltrating the intima of
the pulmonary arteries (r = − 0.35, p = 0.03) (Fig. 1c).
Endothelial function in systemic and pulmonary arteries
Systemic endothelial function assessment
COPD patients and non-COPD subjects showed similar
values for flow mediated dilation (FMD) (1.8 ± 1.0 vs 1.6
± 1.7). FMD was unrelated to the number of circulating
CD45+CD34+CD133+ cells (r = − 0.2, p = 0.3) or to the
presence of CD45+cells in the intima of pulmonary ar-
teries (r = − 0.1, p = 0.4).
Endothelial pulmonary artery function assessment
Endothelium-dependent dilation of isolated pulmonary
arteries induced by ADP and distensibility were reduced
in COPD patients compared to non-COPD subjects
(Table 2). There was no significant correlation between
systemic FMD and pulmonary endothelial function or
between systemic FMD and distensibility (Table 2). The
number of CD45+ infiltrating the artery wall of pulmonary
arteries was inversely correlated with endothelial function
(r = − 0.3, p = 0.05) and distensibility (r = − 0.4, p = 0.04),
whereas the number of circulating CD45+CD34+CD133+
cells did not.
Morphological evaluation
Morphometric measurements of pulmonary arteries are
shown in Table 3. COPD patients had thicker artery
walls (Fig. 2a), reduced lumen area (Fig. 2b), thicker
muscular layer and a trend to thicker intima than
non-COPD subjects (Fig. 2c).
Whereas the number of CD45+ localized in the intima of
the pulmonary arteries inversely correlated with artery
lumen area, the number of circulating CD45+CD34+CD133+
cells did not (Fig. 3a, b).
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Relationships among progenitor cells, pulmonary vascular
remodelling, pulmonary function and CS exposure
In COPD patients, the number of circulating PCs or
bone marrow-derived cells localized in pulmonary arter-
ies was unrelated to the severity of airflow obstruction
or DLco values (Fig. 4a, b). Yet, COPD patients with
DLco values below the median value had greater
pulmonary vascular remodelling, as shown by lower
lumen area, than those with DLco values above the me-
dian value (Fig. 4c). Non-COPD controls were separated
in non-smokers and smokers and compared to COPD
patients (Additional file 2: Table S1). Smokers and
COPD subjects showed a higher percentage of male
subjects than non-smoker controls. In most parameters
analyzed, non-COPD smokers presented an intermediate
phenotype between non-smoker controls and COPD
subjects (FEV1, % predicted; FEV1/FVC, %; DLCO, %
predicted; PaO2, mmHg; CD45
+CD34+CD133+ cells;
mean wall thickness (um); lumen area, % total area and
muscular area, % total area) (Additional file 2: Table S1).
Discussion
The present study shows that in COPD the decrease of
circulating PCs is associated with the presence of bone
marrow-derived cells in pulmonary arteries and the
number of CD45+ cells infiltrating the intima of
pulmonary arteries directly correlated with pulmonary
vascular remodelling.
Circulating CD45+CD34+CD133+ PCs were signifi-
cantly reduced in COPD patients compared with the
non-COPD group, confirming recent findings published
by our group and others [10, 12, 17]. Reduced number
of circulating PCs has been established as a prognostic
risk factor associated with endothelial dysfunction and
increased cardiovascular risk [14]. PCs residing in the
bone marrow under homeostatic conditions can be mo-
bilized into the circulation in response to tissue damage
and are believed to be essential in tissue regeneration
replacing terminally differentiated cells lost because of
physiological cell turnover or tissue damage [10].
The role of PCs in COPD and tissue regeneration is
not fully understood, and different mechanisms have
been suggested to explain the reduced number of circu-
lating PCs seen in COPD patients. One potential explan-
ation is an increased recruitment of these cells to sites of
tissue injury, namely in the pulmonary vasculature. Tis-
sue repair and regeneration following injury is thought
to involve resident cell proliferation as well as a selective
recruitment of circulating progenitor cell populations
through complex signalling cascades [24]. Our group
has previously shown an increased number of CD133+
progenitor cells localized in the wall of pulmonary arter-
ies of COPD patients [22]. Similarly, in this study a
significant number of CD133+ progenitor cells localized
Table 1 Clinical characteristics, lung function and laboratory
measurements
Non-COPD COPD
Age, years 57.3 ± 7.2 58.5 ± 5.8
Male sex, n (%) 9 (64.2%) 24 (96%)
Body mass index (Kg/m2) 24.6 ± 1.7 25.4 ± 2.8
Never smoked, % 5 (35.7%) 0 (0%)
Current smokers, % 6 (43%) 17 (68%)
Ex-smokers, % 3 (21%) 8 (32%)
Smoking history, pack-years 38.6 ± 22.4 60.1 ± 33.9
Expiratory carbon monoxide, ppm 1.5 ± 1.5 2.4 ± 2.2
FEV1, % predicted 91.7 ± 10.5 56.7 ± 21.5***
FEV1/FVC, % 76.2 ± 4.5 51.0 ± 14.7***
TLC, % predicted 90.9 ± 14.5 106.6 ± 17.3*
RV, % predicted 108.8 ± 20.8 164.4 ± 69.2**
DLCO, % predicted 82.5 ± 11.9 63.4 ± 20.1**
PaO2, mmHg 85.0 ± 12.8 75.3 ± 10.5 *
PaCO2, mmHg 37.3 ± 2.8 37.3 ± 3.8
Total cholesterol, mg/dL 196.0 ± 31.4 203.2 ± 39.5
Triglycerides, mg/dL 92.4 ± 25.0 111.2 ± 46.7
HDL, mg/dL 47.0 ± 12.3 48.6 ± 12.1
LDL mg/dL 129.4 ± 28.0 132.4 ± 34.0
Framingham risk score$ 8.4 ± 4.8 10.9 ± 5.7
Glucose, mg/dL 97.1 ± 10.3 100.7 ± 20.5
Leukocyte count, × 109/L 7.7 ± 1.7 8.4 ± 1.5
Lymphocyte count, × 109/L 1.6 ± 0.5 1.8 ± 0.4
Monocyte count, × 109/L 0.4 ± 0.1 0.4 ± 0.1
Neutrophils, ×109/L 5.2 ± 1.5 5.7 ± 1.4
Red blood cells, × 1012/L 4.6 ± 0.4 4.6 ± 0.3
Haemoglobin, g/L 137.0 ± 13.2 146.5 ± 9.3*
Platelet count, × 109/L 309.5 ± 88.0 252.2 ± 61.0*
C-reactive protein, mg/L 1.1 ± 1.5 1.0 ± 2.1
Fibrinogen, mg/L 5.4 ± 1.9 4.0 ± 1.2
Nitrites/nitrates, nMol/mL 20.4 ± 7.0 22.4 ± 10.6
Endothelin-1, pmol/L 6.5 ± 4.3 5.8 ± 2.3
Angiopoietin-2, pg/mL 527.0 ± 99.6 433.3 ± 142.0
VEGF, pg/mL 49.8 ± 41.0 57.8 ± 78.7
VEGFR2, pg/mL 34.4 ± 10.4 53.7 ± 7.8
IL-6, pg/mL 5 ± 7.2 7.7 ± 16.0
BNP. pg/mL 15.9 ± 6.2 21.8 ± 18.2
Definition of abbreviations: COPD chronic obstructive pulmonary disease, DLco
lung diffusing capacity for carbon monoxide, RV residual volume, FEV1 forced
expiratory volume in 1 s, FVC forced vital capacity, TLC total lung capacity,
PaCO2 partial pressure or arterial carbon dioxide, PaO2 partial pressure of
arterial oxygen. Framingham risk score$ can range from −6 to 19, with higher
scores indicating greater cardiovascular risk. Non-COPD (n = 14), COPD (n = 25),
* p < 0.05, ** p < 0.01, *** p < 0.001, compared with non-COPD, Mann Whitney
test. Values expressed as mean ± SD
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within the pulmonary artery of COPD patients suggest-
ing their involvement in pulmonary vessel repair
mechanisms.
In the present study, we extend these previous findings
and show that COPD patients present a greater number
of CD45+ cells in pulmonary arteries than non-COPD
subjects. Interestingly, the number of CD45+ cells within
the pulmonary artery wall was inversely correlated with
the number of circulating CD45+CD34+CD133+ cells,
patients with lower number of circulating PCs had a
higher number of CD45+ cells in the vessel wall. Al-
though this correlation does not establish a cause and
effect relationship, it is plausible that in COPD, progeni-
tor cell mobilization and homing in pulmonary arteries
may occur in response to vascular damage, causing the
depletion of the pool of circulating PCs.
Exposure to CS is the primary cause of COPD and
plays a key role in PC dysfunction [25]. Dysfunctional
PCs show excessive apoptosis and are unable to respond
to external injuries to mediate proper lung tissue healing
[26]. Previous results from our group showed in an ex-
perimental animal model, that short-term exposure to
CS induced PCs dysfunction, affecting pulmonary hom-
ing and proliferation [27]. In vitro, CS altered the rate of
proliferation, senescence, differentiation and migration
capacity of PCs [27]. In COPD patients, dysfunctional
PCs may be unable to support the normal repair of the
pulmonary vasculature promoting neointima formation,
vessel remodelling and disease progression. In line with
these results, our group has previously shown that bone
marrow derived CD133+ cells had the capacity to mi-
grate from the vessel lumen into the intima and differen-
tiate into smooth muscle cells, exerting remodelling
effects on injured vessels [28].
In the present study, COPD patients displayed thicker
pulmonary artery walls and reduced lumens than
non-COPD subjects. Interestingly, the increased number
of CD45+ cells localized in the pulmonary artery wall
was associated with a reduction in the arterial lumen.
This is in agreement with previous observations from
our group showing that structural alterations in pulmon-
ary arteries occur at early stages in COPD and that the
number of CD133+ cells attached to the endothelium
was greater in COPD patients than in control subjects
[23]. Overall, the current and previous findings suggest a
potential causative role of progenitor cell recruitment in
the pathogenesis of pulmonary vascular remodelling in
COPD.
COPD patients and non-COPD subjects showed simi-
lar values of systemic endothelial function, though both
a b c
Fig. 1 Number of CD45+CD34+CD133+ and CD45+ cells in COPD. a Number of circulating CD34+CD133+CD45+ progenitor cells in non-COPD and
COPD patients expressed as percent of lymphomonocytes; (b) Quantification of CD45+ infiltrates in the intima of the pulmonary arteries
expressed as a number per mm of endothelium in non-COPD and COPD subjects, * P < 0.05, compared with non-COPD subjects, Mann Whitney
test. Values expressed as mean ± SD; (c) Relationship between the number of CD45+cells and the number of circulating CD45+CD34+CD133+
cells; Spearman rank correlation test, Non-COPD (n = 13), COPD (n = 24), * P < 0.05
Table 2 Endothelial function and distensibility of pulmonary
arteries
Non-COPD COPD
ADP-induced vasodilation, % change
from maximal contraction
−88.2 ± 26.0 −83.5 ± 22.6
Distensibility, vol/mmHg 2.0 ± 0.8 1.4 ± 0.5*
Definition of abbreviations: ADP adenosine diphosphate. Non-COPD (n = 11),
COPD (n = 23), Mann Whitney test. Values expressed as mean ± SD. * p < 0.05
Table 3 Morphometric measurements on pulmonary arteries
Variables Non-COPD COPD
Mean wall thickness (μm) 44.1 ± 14.1 56.6 ± 15.8*
Measured external diameter (μm) 210.7 ± 61.0 252.3 ± 120.5
Calculated external diameter, um 538.4 ± 147.9 531.1 ± 117.2
Index of narrowing, % 73.5 ± 3.9 72.8 ± 8.1
Wall thickness, % measured diameter 34.0 ± 9.6 41.0 ± 16.5
Intimal area, % total area 22.8 ± 8.9 24.7 ± 7.2
Muscular area, % total area 32.8 ± 8.9 43.4 ± 5.9***
Lumen area, % total area 42.3 ± 12.8 31.8 ± 7.7**
Definition of abbreviations: COPD chronic obstructive pulmonary disease; Non-
COPD (n = 9), COPD (n = 23), * p < 0.05, ** p < 0.01, *** p < 0.001 compared
with non-COPD, Mann Whitney test. Values are expressed as mean ± SD
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groups had lower values than those previously observed
in healthy non-smokers [17]. This indicates that both
COPD patients and non-COPD subjects in this study
presented systemic endothelial dysfunction. We have
previously reported significant differences in FMD values
between control non-smokers and both COPD patients
and smokers without COPD [17]. Accordingly, the
reduced value of FMD shown herein in the non-COPD
group is likely due to the fact that most of the
non-COPD subjects were heavy smokers. When the
non-COPD group was divided in non-smokers and
smokers a marked increase of FMD was seen in the
non-smoker group compared to the smoker control
group. We also observed that FMD values were unre-
lated to the number of circulating PCs or CD45+ cells
localized in the pulmonary artery wall. This agrees with
previous findings where no significant correlation was
found between the number of circulating PCs and FMD
values between COPD and non-COPD subjects [17].
Endothelium-dependent dilation and distensibility
values measured in isolated pulmonary arteries were re-
duced in COPD patients compared to non-COPD
subjects and correlated with the number of infiltrating
CD45+ cells in pulmonary arteries. This is consistent
with the notion that impairment of the endothelial
function in pulmonary arteries may promote the
mobilization and homing of bone marrow-derived PCs.
Systemic endothelial dysfunction did not correlate with
pulmonary endothelial dysfunction. We consider that
endothelial dysfunction in systemic arteries is more
likely due to chronic CS exposure rather than a systemic
effect of COPD. On the other hand, pulmonary endothe-
lial dysfunction appears to be more directly related to
progenitor cell homing in response to injury and vessel
remodelling. Overall, these findings suggest that CS
might exert direct effects on endothelial function in both
systemic and pulmonary arteries, irrespective of the
number of recruited PCs in remodelled pulmonary
arteries.
DLco values were not associated with variations in the
number of circulating PCs or bone marrow-derived cells
recruited in pulmonary vessels. Yet, lower DLco values
were associated with greater remodelling of pulmonary
arteries. Neither the severity of airflow obstruction nor
Fig. 2 Morphometric measurements in non-COPD and COPD
subjects. a Percentage of artery wall thickness, % measured radius;
(b) Percentage of lumen area, % total area; (c) Percentage of muscular area, % total area in non-COPD and COPD subjects. Non-COPD
(n = 13), COPD (n = 23), * P < 0.05, ** P < 0.01compared with non-COPD subjects, Mann Whitney test. Values expressed as mean ± SD
a b
Fig. 3 CD45+CD34+CD133+, CD45+ cells and the percentage of artery lumen. a Relationship between the number of CD45+CD34+CD133+ cells and the
percentage of lumen area, % total area artery lumen of pulmonary arteries; (b) Relationship between the number of CD45+ cells and the percentage of
lumen area, % total area artery lumen of pulmonary arteries. Non-COPD (n= 11), COPD (n= 21), Spearman rank correlation test, * P< 0.05
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the values of PaO2, were related to changes in PCs or
pulmonary vascular remodelling. Overall, our findings
are in line with the notion that DLco is a marker of
pulmonary vascular integrity. Finally, non-COPD con-
trols were separated in non-smokers and smokers and
compared to COPD patients. In most parameters ana-
lyzed, non-COPD smokers presented an intermediate
phenotype between non-smoker controls and COPD
subjects indicating the key role of CS exposure in lung
and endothelial dysfunction.
The main strength of this study was the simultan-
eous measurement of markers of vascular integrity
and function in both systemic and pulmonary arter-
ies, using lung tissue samples, in the same individual.
Nevertheless, our study has some limitations. First,
the reduced number of subjects, which is inherent to
the need to evaluate patients undergoing lung resec-
tion in whom the lung neoplasm was localized and
did not produce changes in lung parenchyma or re-
spiratory function. Second, the CD45 maker used in
tissue assessment is not specific to progenitor cells
and could also indicate recruitment of other cell
populations. Further studies using double staining for
both CD133 and CD45 immunofluorescence are re-
quired to prove that these migrated cells in the
intima of the pulmonary arteries are derived from
circulating PCs. Third, in this study we could not be
certain that the number of CD45+ cells present in
the pulmonary walls and the reduced artery lumen
area, were directly associated to the reduced number
of circulating CD45+CD34+CD133+ cells in these pa-
tients. However, the direct correlation between the
number of circulating CD45+CD34+CD133+ cells and
the number of CD45+ infiltrates in pulmonary vessels
and the presence of CD133+ cells, an intrinsic
marker of progenitor cells, observed in the vessel
wall might infer that in COPD patients, circulating
CD45+CD34+CD133+ cells are recruited in response
to injury to the pulmonary vessel wall, causing a re-
duction in circulating PCs numbers.
Interestingly, recent data suggested the existence of a
“vasculogenic zone” in the wall of human blood vessels,
which might serve as a reservoir for PCs capable to dif-
ferentiate into mature endothelial cells [29]. Accordingly,
the presence of PCs recruited as a result of an injury
response could not solely be explained by the homing of
bone-marrow derived circulating PCs as tissue resident
PCs could also play an important role. Finally, some of
the results are represented as correlations and therefore
only describe an association, they do not prove a cause
and effect relationship.
Conclusion
This integrative study shows a reduction of circulating
PCs in COPD, which is associated with the recruitment
of bone marrow-derived cells into the patient’s pulmon-
ary artery wall. This, in turn, is associated with endothe-
lial dysfunction and vessel remodelling of pulmonary
arteries. Overall, our results suggest the contribution of
bone marrow-derived PCs in pulmonary vascular re-
modelling and are consistent with the notion of an
imbalance between endothelial damage and repair cap-
acity in the pathogenesis of pulmonary vascular abnor-
malities in COPD.
Additional files
Additional file 1: Figure S1. Immunolocalization of CD45+ and
CD133+cells in pulmonary arteries. (a) Representative micrograph of a
transversal section of a pulmonary artery (around 2mm diameter) stained
with a monoclonal antibody against CD45 (arrows are showing positive
cells in the intima layer). (b) Representative micrograph of a transversal
section of a pulmonary artery stained with a monoclonal antibody
against CD133 (arrows are showing positive cells in the intima and
sometimes in the media layer). (PDF 706 kb)
Fig. 4 CD34+CD133+CD45+, CD45+ cells and % of artery lumen and DLco levels. a Number of circulating CD34+CD133+CD45+progenitor cells in
non-COPD and COPD patients grouped according to DLco above or below the median value (60% predicted); (b) Number of CD45+cells in non-
COPD and COPD subjects grouped according to DLco above or below the median value (60% predicted); (c) % of artery lumen in non-COPD and
COPD subjects grouped according to DLco above or below the median value (60% predicted). Non-COPD (n = 11), COPD (n = 21), * P < 0.05,
Mann Whitney test. Values expressed as mean ± SD
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Additional file 2: Table S1. Clinical characteristics, lung function,
endothelial function, PCs numbers and morphometric measurements.
(DOCX 16 kb)
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